Research Topics
Genomes and GenesSpecies | M GarzottoSummaryAffiliation: Oregon Health and Science University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Advances in the multimodality management of high-risk prostate cancerMark Garzotto
Department of Urology, Portland Veterans Administration Medical Center, Oregon Health and Science University, Portland, OR 97239, USA
Surg Oncol Clin N Am 22:375-94. 2013..The combination of early cancer detection and technical improvements in local treatment has led to a reduction in disease burden and an increase in cancer survivorship. However, treatment failure remains common among high-risk cases...
Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancerMark Garzotto
Urology Section, Surgical Service, Portland VA Medical Center, Portland, OR 97239, USA
Urol Oncol 24:254-9. 2006..The goal of this phase I/II study is to evaluate the safety and efficacy of neoadjuvant docetaxel and mitoxantrone before prostatectomy...- Improved detection of prostate cancer using classification and regression tree analysisMark Garzotto
Urology Section, Division of Urology, Portland Veterans Administration Medical Center, 3710 SW US Veterans Hospital Rd, Portland, OR 97239, USA
J Clin Oncol 23:4322-9. 2005..To build a decision tree for patients suspected of having prostate cancer using classification and regression tree (CART) analysis... - Combined androgen deprivation with radiotherapy for prostate cancer: does it make sense?M Garzotto
Urology Section, Portland Veterans Administration Medical Center, Portland, Oregon 97201, USA
Mol Urol 4:209-13;discussion 215. 2000..Thus, paradoxically, AD may reduce the radiosensitivity of prostate cancer by means of cell-cycle delay, which results in a reduction in postmitotic apoptosis... - Recursive partitioning for risk stratification in men undergoing repeat prostate biopsiesMark Garzotto
Urology Section, Portland Veterans Administration Medical Center, Portland, Oregon 97239, USA
Cancer 104:1911-7. 2005..The current study was performed to identify risk factors and risk groups for carcinoma detection in men undergoing repeat prostate biopsies... - Contemporary management of high-risk localized prostate cancerMark Garzotto
Division of Urology, Department of Surgery, and the Department of Radiation Medicine, Oregon Health and Science University, Portland Veterans Administration Medical Center, Portland, OR, 97239, USA
Curr Urol Rep 11:159-64. 2010..It is likely that the development of effective strategies based on understanding prostate tumor biology will lead to significant advances in the treatment of this disease... 
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancerT M Beer
Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Mail Code CR145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
Br J Cancer 91:1425-7. 2004..Intermittent chemotherapy for AIPC is feasible and deserves further study...- Weekly high-dose calcitriol and docetaxel in advanced prostate cancerT M Beer
Department of Medicine, Oregon Health Sciences University and the Portland Veterans Affairs Medical Center, Portland, OR 97201, USA
Semin Oncol 28:49-55. 2001..Treatment has been well tolerated, with 1 patient experiencing a self-limited grade 3 toxicity and no patients experiencing grade 4 or 5 toxicities... - Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohortM el-Geneidy
Oregon Health and Science University, Department of Medicine, Division of Hematology and Medical Oncology, Oregon, USA
BJU Int 93:510-5. 2004..Age and percentage positive biopsy cores are independent predictors of such intervention, with PSA doubling time also an independent predictor... - Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cellsJ Dai
Department of Urology, Urological Oncology Research Laboratory, Joan and Stanford I. Weill Medical College of Cornell University, New York, New York 10021, USA
Clin Cancer Res 7:1370-7. 2001..These data show that NEP can inhibit PC cell growth and tumorigenicity and suggest that NEP has potential as therapy for androgen-independent PC... - Intermittent chemotherapy in metastatic androgen-independent prostate cancerT M Beer
Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Mail Code L586, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
Br J Cancer 89:968-70. 2003..Chemotherapy holiday was associated with an improvement of fatigue (P=0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study... - Erythrocyte fatty acids and prostate cancer risk: a comparison of methodsJ Shannon
Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239 3098, USA
Prostaglandins Leukot Essent Fatty Acids 83:161-9. 2010..We provide an example of modeling FA and their inter-relationships on the risk of prostate cancer. Comparing three approaches suggests the importance of considering the impact of the entire fatty acid profile in disease prevention... - Current concepts in risk factor assessment for advanced germ cell cancerM Garzotto
Urology Section, Portland Veterans Administration Medical Center Urology Division, USA
Semin Urol Oncol 19:165-9. 2001..The development of this system has allowed for valid comparisons of ongoing and future trials. Furthermore, this system will serve to encourage international collaboration for the study of high-risk GCT... - Effect of calcitriol on prostate-specific antigen in vitro and in humansTomasz M Beer
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
Clin Cancer Res 12:2812-6. 2006..We examined the effects of calcitriol at similar concentration on cell proliferation, androgen receptor (AR) expression, and PSA production in vitro and on PSA concentrations in prostate cancer patients... - Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient miceXi Zheng
Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway 08854, USA
Clin Cancer Res 12:3444-51. 2006..Clinical trials with TPA alone or in combination with paclitaxel in patients with prostate cancer may be warranted... - Testosterone loss and estradiol administration modify memory in menTomasz M Beer
Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
J Urol 175:130-5. 2006..We characterized the impact of androgen deprivation and of subsequent estradiol therapy on the long-term and working memory of patients with prostate cancer... - Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancerTomasz M Beer
Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Mail Code CR 145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
Cancer Chemother Pharmacol 59:581-7. 2007..DN-101 is a new, high-dose, oral formulation of calcitriol under investigation for the treatment of cancer. We sought to evaluate the tolerability and pharmacokinetics (PK) of weekly doses of DN-101 in patients with advanced cancer... - Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?Jennifer L Lycette
Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
Clin Genitourin Cancer 5:198-205. 2006.... - Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes studyJulie N Graff
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
J Urol 177:1307-12. 2007..We determined which demographic and clinical factors predict overall and cancer specific survival with this treatment strategy in patients enrolled in the Prostate Cancer Outcomes Study... - Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsyStephen E F Spurgeon
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
Urology 69:931-5. 2007..We hypothesized that the prebiopsy PSA doubling time (PSADT) and PSA velocity (PSAV) could predict for cancer detection in a referral population with a suspicion of prostate cancer... - Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancerR Bruce Montgomery
Department of Medicine, Veterans Affairs Puget Sound Health Care System VAPSHCS, and University of Washington School of Medicine, Seattle, WA 98108, USA
Cancer 110:996-1002. 2007..The addition of diethylstilbestrol to docetaxel modified tubulin composition and improved the response of prostate cancer to chemotherapy in preclinical models. An attempt was made to recapitulate the observations in a clinical trial... - Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancerBruce Montgomery
Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington 98109, USA
Urology 72:474-80. 2008 - Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancerDaniel M Janoff
Division of Urology, Oregon Health and Science University and Portland VA Medical Center, Oregon 97239, USA
BJU Int 96:503-7. 2005..Toxicity, principally in the form of bone fractures, was high... - High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II studyNatasha M Tiffany
Division of Hematology and Medical Oncology, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, Portland 97239, USA
J Urol 174:888-92. 2005..One of 11 patients (9%) treated with prior docetaxel met these criteria. CONCLUSIONS: High dose calcitriol may be safely added to docetaxel and estramustine administered on a 21-day schedule... - Statins and prostate cancer risk: a case-control studyJackilen Shannon
Oregon Health and Sciences University, Portland, OR 97239 3098, USA
Am J Epidemiol 162:318-25. 2005..24, 95% confidence interval: 0.11, 0.53). The results of this case-control study suggest that statins may reduce the risk of total prostate cancer and, specifically, more aggressive prostate cancer... - Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancerTomasz M Beer
Oregon Health and Science University and Portland VA Medical Center, Portland, OR 97239, USA
J Clin Oncol 21:123-8. 2003.... - Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomyTomasz M Beer
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
Urology 63:342-7. 2004..None of the patients met the PSA response criteria; nonetheless, minor reductions in serum PSA were observed in 5 of 16 patients... - Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mLMark Garzotto
Division of Urology, Portland Veterans Administration Medical Center, Portland, Oregon
Cancer 98:1417-22. 2003..Predictive nomograms may serve as an aid to patient counseling regarding prostate biopsy outcome and to reduce the number of unnecessary biopsy procedures... - Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinomaTomasz M Beer
Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland 97239, Oregon, USA
Cancer 100:758-63. 2004..The current study evaluated the analgesic activity and impact on quality of life (QOL) of a new chemotherapy regimen of calcitriol and docetaxel in men with androgen-independent prostate carcinoma... - Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancerTomasz M Beer
Divisions of Hematology and Medical Oncology, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
Clin Cancer Res 10:1306-11. 2004..The purpose is to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of mitoxantrone and docetaxel administered weekly before prostatectomy in men with localized prostate cancer at high risk for recurrence... - Predictors of delayed therapy after expectant management for localized prostate cancer in the era of prostate-specific antigenIrene Panagiotou
Division of Hematology and Medical Oncology, Cancer Institute, Oregon Health and Science University, Portland, OR, USA
Oncology 67:194-202. 2004..Gleason score and percent of positive biopsy cores predict cancer-directed interventions, thus, these patients may be least suitable for expectant management... - High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancerTomasz M Beer
Department of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA
Am J Clin Oncol 27:535-41. 2004..Despite encouraging preclinical evidence, the addition of oral calcitriol to carboplatin in this study was not associated with an increase in the response rate when compared with the reported activity of carboplatin alone... - Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomyTomasz M Beer
Division of Hematology and Medical Oncology, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, CR 145, Portland, OR 97239, USA
Cancer Epidemiol Biomarkers Prev 13:2225-32. 2004..In this study, we selected this approach to test several hypotheses about the effect of calcitriol (1,25-dihydroxycholecalciferol), the active form of vitamin D, on early-stage human prostate cancer... - Phase II study of transdermal estradiol in androgen-independent prostate carcinomaLisa B Bland
Division of Urology, Oregon Health and Science University and Portland Veterans Affairs Medical Center, Portland, Oregon, 97239, USA
Cancer 103:717-23. 2005..CONCLUSIONS: In patients with APIC, TDE was well tolerated and produced a modest response rate, but was not associated with thromboembolic complications or clinically important changes in several coagulation factors... - Radical retropubic prostatectomy after orthotopic liver transplantationAaron Bayne
Division of Urology and Renal Transplantation, Oregon Health and Science University, Portland, Oregon, USA
Urology 65:175. 2005..In each case, the prostate tumor was organ confined, and both patients were biochemically free of disease at last follow-up... - Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancerJonathan Q Purnell
Department of Medicine, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, OR 97239, USA
J Lipid Res 47:349-55. 2006..Compared with ADT, short-term TDE therapy of prostate cancer improves lipid levels without deterioration of CVD-associated inflammatory markers and may, on longer-term follow-up, improve CVD and mortality rates... - Resistance of prostate cancer cell lines to COX-2 inhibitor treatmentMatthew Wagner
Division of Urology and Renal Transplantation, Oregon Health and Science University, Oregon Cancer Institute, Portland, OR, USA
Biochem Biophys Res Commun 332:800-7. 2005..In conclusion, these studies indicate the lack of a putative role for COX-2 in prostate cancer development. Direct evidence for the involvement of COX-2 in prostate cancer carcinogenesis is desperately needed... - A comparison of CT scan to transrectal ultrasound-measured prostate volume in untreated prostate cancerS Christopher Hoffelt
Department of Radiation Oncology, Oregon Health Sciences University, Portland, OR 97239, USA
Int J Radiat Oncol Biol Phys 57:29-32. 2003..CONCLUSION: A strong correlation was found between CT scan and TRUS measurement of the prostate volume; however, CT consistently overestimated the prostate volume by approximately 50% compared with TRUS... - Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15Chung Ying Huang
Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98105 1024, USA
Clin Cancer Res 13:5825-33. 2007..To identify molecular alterations associating with in vivo exposure of prostate carcinoma to chemotherapy and assess functional roles modulating tumor response and resistance... - Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancerMatthew Wagner
Division of Urology, Oregon Health and Science University, Portland, Oregon 97239, USA
Urology 65:799. 2005..Additional observations are needed to determine whether this is an isolated case or a harbinger of a more common phenomenon... - Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsyStephen E F Spurgeon
Divisions of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
J Urol 175:918-22. 2006..CONCLUSIONS: CART identified groups at risk for aggressive prostate cancer. Application of this CART could decrease unnecessary biopsies by 33.5% when only a diagnosis of high grade prostate cancer would lead to subsequent therapy... - Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapyTomasz M Beer
Division of Hematology, Oregon Health and Science University, Portland, OR, USA
J Urol 169:1738-41. 2003..CONCLUSIONS: Treatment of androgen independent prostate cancer with abarelix decreases circulating FSH and maintains anorchid testosterone but does not result in clinical responses... - Metastatic adenocarcinoma of prostate in a healing sternotomy siteGreg Adams
Division of Urology and Renal Transplantation, Oregon Health and Science University, Portland, Oregon, USA
Urology 68:204.e13-5. 2006....